RecruitingPhase 3NCT06846281
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Studying Opsoclonus-myoclonus syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Intervention
- Remibrutinib oral treatment(drug)
- Enrollment
- 360 target
- Eligibility
- 40-70 years · All sexes
- Timeline
- 2025 – 2031
Study locations (30)
- Perseverance Research Center, Scottsdale, Arizona, United States
- Medstar Washington Hospital Center, Washington D.C., District of Columbia, United States
- Neurology of Central FL Res Ctr, Altamonte Springs, Florida, United States
- University of Florida, Gainesville, Florida, United States
- Neurology Associates PA, Maitland, Florida, United States
- Aqualane Clinical Research, Naples, Florida, United States
- Advent Health Orlando, Orlando, Florida, United States
- Orlando Health Clinical Trials, Orlando, Florida, United States
- Tallahassee Neurological Clinic, Tallahassee, Florida, United States
- University Of South Florida, Tampa, Florida, United States
- Vero Beach Neurology, Vero Beach, Florida, United States
- Rush University Medical Center, Chicago, Illinois, United States
- University of Kansas Hospital, Kansas City, Kansas, United States
- MedStar Montgomery Medical Center, Olney, Maryland, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06846281 on ClinicalTrials.govOther trials for Opsoclonus-myoclonus syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07485517Deep Versus Moderate Neuromuscular BlockingMenoufia University
- ACTIVE NOT RECRUITINGNANCT07419815IV Lidocaine Infusion Versus Placebo for Pain Control in Staging Laparoscopy CasesShaukat Khanum Memorial Cancer Hospital & Research Centre
- RECRUITINGNANCT07473648Multimodal Clinical Study of Electroconvulsive Therapy and Magnetic Seizure TherapyThe Second Hospital of Anhui Medical University
- ACTIVE NOT RECRUITINGNCT07144410Pain Control and Side Effects in Cesarean Section Anesthesia: Comparison of Intrathecal Morphine and FentanylUniversity of Oradea
- RECRUITINGPHASE2NCT07036406Comparing Traditional Semantic Feature Analysis (tSFA) and Semantic Feature Analysis + Metacognitive Strategy Training (SFA+MST)Teachers College, Columbia University
- RECRUITINGPHASE4NCT06797973Efficacy and Safety of Intrathecal Morphine for Postoperative Pain Management Following Planned Caesarean SectionAnne Juul Wikkelsø
- RECRUITINGPHASE3NCT06847724Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple SclerosisSandoz
- RECRUITINGPHASE4NCT06878014Comparing the Safety and Effectiveness of Different Doses of Morphine Administered in Spinal Anethesia for Pain Relief After Hip Replacement SurgeryMedical University of Silesia